At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 261 enrolled
Drug / intervention
placebo +1 moredrug
Likely dose
exenatide 10mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
In Brief
A Phase 3 clinical trial evaluating placebo and exenatide for Type 2 Diabetes. Completed, enrolled 261 participants across 59 sites in 6 countries.
Detailed Summary
This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesGreece, Israel, Mexico, Puerto Rico, United Kingdom, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedOct 3, 2008
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.7 years ago
Interventions
placebodrug
subcutaneous injection, twice a day
exenatidedrug
subcutaneous injection, twice a day, 10mcg